Choose Better Outcomes. Choose FLOSEAL.
Inadequate surgical hemostasis and uncontrolled bleeding may lead to transfusion and/or other bleeding-related complications1, lower clinical outcomes and higher hospital costs2.
During the last 20 years, FLOSEAL Hemostatic Matrix has been shown to result in better clinical and hospital resource utilization outcomes.
Take an Active Approach to Hemostasis
FLOSEAL consists of a unique combination of patented gelatin granules and human thrombin to provide fast (2 min median time to hemostasis), effective hemostasis. Learn more about how FLOSEAL works.
Additional Product Benefits
The Leader in Hemostasis
For certain surgical procedures, use of FLOSEAL Hemostatic Matrix is associated with shorter length of surgery3, fewer intensive care unit days4, significantly lower risks of complications, blood transfusions and surgical revisions5.
FLOSEAL has been proven to perform fast and consistently across a range of bleeds6.
Health Economic Benefits
The use of FLOSEAL can result in improved Resource Utilization Outcomes and substantial Cost Savings for hospitals – up to $1.5M per year7 and $2,445 per spine procedure8.
FLOSEAL Hemostatic Matrix Indication
FLOSEAL Matrix is indicated in surgical procedures (other than ophthalmic) as an adjunct to hemostasis when control of bleeding by ligature or conventional procedures is ineffective or impractical.
Full important risk information
Do not inject or compress FLOSEAL Matrix into blood vessels. Do not apply FLOSEAL Matrix in the absence of active blood flow, e.g., while the vessel is clamped or bypassed, as extensive intravascular clotting and even death may result.
Do not use FLOSEAL Matrix in patients with known allergies to materials of bovine origin. Do not use FLOSEAL Matrix in the closure of skin incisions because it may interfere with the healing of the skin edges.
FLOSEAL Matrix contains Thrombin made from human plasma. It may carry a risk of transmitting infectious agents, e.g., viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent.
FLOSEAL Matrix is not intended as a substitute for meticulous surgical technique and the proper application of ligatures or other conventional procedures for hemostasis.
Excess FLOSEAL Matrix (material not incorporated in the hemostatic clot) should always be removed by gentle irrigation from the site of application.
FLOSEAL Matrix swells by approximately 10% to 20% after product is applied. Maximum swell volume is achieved within about 10 minutes.
The safety and effectiveness of FLOSEAL Matrix has not been established in children under 2 years of age and pregnant women.
Do not use air to remove residual FLOSEAL Matrix from Applicator tip. The Applicator tips should not be cut. Do not use FLOSEAL Matrix on bone surfaces where adhesives, such as methylmethacrylate or other acrylic adhesives, will be required to attach a prosthetic device.
Rx Only. For safe and proper use of this device, refer to the full Instructions for Use.
FLOSEAL Full Instructions for Use: